Concepedia

Author

Joshua J. Skydel

Yale UniversityORCID

Also Known As

Joshua J Skydel, Joshua J. Skydel

17

Publications

209

Citations

8

H-Index

18

Concepts

All Affiliations

Yale UniversityYale New Haven Health SystemTufts UniversityUniversity of California, San FranciscoYale New Haven Hospital
JJ

About

Joshua J. Skydel is an author at Yale University specializing in public health, outcomes research, and clinical trial design.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

23

2

Public Health

1

1

23

3

Epidemiology

1

1

23

4

Health Policy

1

1

23

5

Clinical Effectiveness

1

1

23

Joshua J. Skydel

×

8

Publications

191

Citations

8

H-Index

YearCitations

Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics

Tanvee Varma, Joshua D. Wallach, Jennifer Miller,

JAMA Network Open

2021

41

Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open access publishing each year

Mallory K. Ellingson, Xiaoting Shi, Joshua J. Skydel,

BMJ Open

2021

27

Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019

Marissa H. Elliott, Joshua J. Skydel, Sanket S. Dhruva,

JAMA Internal Medicine

2020

23

Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval

Joshua D. Wallach, Audrey D. Zhang, Joshua J. Skydel,

JAMA Network Open

2021

23

US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018

Joshua J. Skydel, Audrey D. Zhang, Sanket S. Dhruva,

Clinical Trials

2021

22

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments

Joshua J. Skydel, Anita T. Luxkaranayagam, Sanket S. Dhruva,

JAMA Network Open

2019

21

Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study

Osman Moneer, Garrison Daly, Joshua J. Skydel,

BMJ

2022

21

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017

Joshua J. Skydel, Alexander C. Egilman, Joshua D. Wallach,

JAMA Health Forum

2022

13

Page 1